Loading…
FOCL
Edap Tms SA
NASDAQ· Healthcare· Medical Distribution· CUSIP 268311107
$4.31-0.69%Price as of Aug 29, 18:38 UTC · updated once a day, after the close
Key metrics
- Market cap
- $198.06M
- P/E
- —
- Forward P/E
- —
- P/B
- —
- Dividend yield
- —
- Payout
- —
- EPS
- -$1.04
- ROE
- -265.67%
- Profit margin
- -49.13%
- Revenue growth
- +38.80%
- Beta
- -0.03
- 52-week high
- $6.40
- 52-week low
- $1.75
History
How the company evolved, year by year. Revenue and debt come from the annual reports — for most companies, the 10-K filings with the SEC since 2009; dividends from the payments themselves.
The bars are a balance on the closing date; the lines are what happened during the year. Revenue above equity is ordinary, not an anomaly — it means the company turns its capital over more than once a year.
Investors holding this
Major managers that reported this stock in their latest 13F.
Price over time
▼ -22.5% over 5Y.
today you would have $738.24▼ -26.2%
Dividends reinvested, splits accounted for. Past prices say what happened, not what will.
Indicators, year by year
The last 2 closed years. Each multiple uses that year’s closing price and that year’s reported numbers — not today’s. The range is set by the annual reports on record.
| Indicator | Median | 2025 | 2024 |
|---|---|---|---|
| Year-end price | $3.29 | $2.21 | |
| P/S | — | 1.7x | 1.2x |
| P/B | — | 6.4x | 1.9x |
| EPS | -$0.78 | -$0.55 | |
| Profit margin | — | -41.47% | -29.66% |
| ROE | — | -150.65% | -48.45% |
Median, not average: a single year of near-zero profit produces a P/E of 400 and would drag an average on its own. P/E years above 200x are left out, the same cut the fair price uses — so this median matches the “its own history” method below. Price and EPS have no median: they are series that grow.
Others in the same sector
Companies of similar size in Healthcare, for comparison. The columns are the same ones above, in the same order.
| Stock | Price | P/E | P/B | Dividend yield | ROE | Market cap |
|---|---|---|---|---|---|---|
| DTILPrecision Biosciences Inc | $7.19 | — | 4.2x | — | -135.15% | $198.46M |
| ACOGAlpha Cognition Inc. | $9.16 | — | 3.8x | — | -49.53% | $199.49M |
| ARMPArmata Pharmaceuticals, Inc. | $5.37 | — | — | — | — | $199.67M |
| PDEXPro Dex Inc | $62.56 |
About the company
EDAP TMS S.A., doing business as FocalTherics, operates as a medical technology company that develops, manufactures, markets, and sells non-invasive therapeutic ultrasound and energy-based medical devices in Asia, France, the United States, and internationally. The company develops, manufactures, markets, and distributes non-invasive robotic HIFU systems for urology-related and other indications. It also offers Focal One, a HIFU robotic system to treat patients diagnosed with prostate cancer, as well as disposables, and leasing and treatment related services; and maintenance services. In addition, the company manufactures and markets lithotripter for the treatment of urinary tract stones; and provides disposables, replacement parts, and services for lithotripters; and sells spare parts and disposables, such as electrodes. Further, it markets, distributes, and services lasers, micro-ultrasound systems, and other medical products from third parties, as well as leases devices; sells disposables and spare parts; and offers maintenance services. The company markets and sells its products through its direct marketing, sales channels, and third-party distributors and agents. The company serves academic, public, and private hospitals, as well as clinics. The company has a strategic collaboration with Telix Pharmaceuticals Limited to develop clinical workflows combining PSMA PET imaging and Focal One Robotic HIFU for prostate cancer. EDAP TMS S.A. was incorporated in 1979 and is headquartered in Vaulx-en-Velin, France.
- 289
- Vaulx-En-Velin, France
Company description provided by Yahoo Finance.